
FDA Grants Fast Track Designation to RAD101 for Imaging of Brain Metastases
The FDA has granted fast track designation to RAD101, an investigational imaging agent, to differentiate between recurrent brain metastases and treatment-related effects in patients with cerebral metastases originating from various solid tumors, including …